Darifenacin Hydrobromide

CAS 133099-07-7 13 current records 6 historicalSmall Molecule

Who holds supplier records for Darifenacin Hydrobromide? 13 organisations hold a current record for Darifenacin Hydrobromide: an active US FDA Type II Drug Master File. A further 6 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (10), Canada (1) and Netherlands (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Darifenacin Hydrobromide: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/darifenacin-hydrobromide

Reading the evidence

  • 13 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    10 of the 12 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (13)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Darifenacin Hydrobromide. Country is the organisation's recorded country, not necessarily the manufacturing site.

India10Canada1Netherlands1Country not recorded for 1
Need Darifenacin Hydrobromide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (6)

Organisations whose Type II DMFs for Darifenacin Hydrobromide are no longer active. These show a past filing, not current supply.

Show all 6 historical records

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Darifenacin Hydrobromide is an antimuscarinic drug used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It works by inhibiting the M3 muscarinic acetylcholine receptor, which relaxes bladder smooth muscle.

Chemical identity

IUPAC name
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
Canonical SMILES
C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br
InChIKey
UQAVIASOPREUIT-VQIWEWKSSA-N
Synonyms
Enablex API, darifenacin hbr, emselex, enablex, uk-88525-04 (hbr), uk-88525-04 (hydrobromide)

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Cholinergic Muscarinic Antagonist
Mechanism of action
Cholinergic Muscarinic Antagonists

Therapeutic areas

UrologyGynecologyNephrology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Darifenacin Hydrobromide?

13 organisations hold an active US FDA Type II Drug Master File or a CEP for Darifenacin Hydrobromide: Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India), Apotex Inc. (Canada), Cipla Limited (India), Emcure Pharmaceuticals Limited (India), JUBILANT BIOSYS LTD (India) and Macleods Pharmaceuticals Ltd. (India), and 5 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Darifenacin Hydrobromide Drug Master Files are active?

Alembic Pharmaceuticals Limited (DMF 26138), ALIVUS LIFE SCIENCES LTD (DMF 22184), APITORIA PHARMA PRIVATE LTD (DMF 27551), Apotex Inc. (DMF 26824), Cipla Limited (DMF 28085), Emcure Pharmaceuticals Limited (DMF 26814), JUBILANT BIOSYS LTD (DMF 26719) and Macleods Pharmaceuticals Ltd. (DMF 27047) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Darifenacin Hydrobromide records mean?

6 organisations have only inactive Type II DMFs for Darifenacin Hydrobromide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Darifenacin Hydrobromide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Darifenacin Hydrobromide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.